

I. AMENDMENTS TO THE CLAIMS

Claim 148. (Currently Amended) A method for the treatment of an autoimmune inflammatory disease or disorder in a subject in need of the treatment, comprising a step of administering an autoimmune inflammatory disease or disorder treatment effective amount of a composition to said subject, wherein the composition comprises boswellic acids, and wherein the boswellic acids consist essentially of

β -boswellic acid of ~~at least~~ 5% to 95% by weight,
acetyl- β -boswellic acid of ~~at least~~ 5% to 95% by weight,
11-keto- β -boswellic acid of ~~at least 15%~~ 1% to 95% by weight and
acetyl-11-keto- β -boswellic acid of ~~at least 14%~~ 1% to 95% by weight, and
wherein said subject is a human or animal.

Claim 149. (Canceled)

Claim 150. (Currently Amended) The method of ~~claim 149~~ claim 148, wherein the composition comprises boswellic acids, and wherein the boswellic acids consist essentially of

β -boswellic acid of ~~at least 12%~~ 12% to 35% by weight,
acetyl- β -boswellic acid of ~~at least 5%~~ 5% to 35% by weight,
11-keto- β -boswellic acid of ~~at least 15%~~ 15% to 45% by weight and
acetyl-11-keto- β -boswellic acid of ~~at least 14%~~ 14% to 45% by weight.

Claim 151. (Canceled)

Claim 175. (Currently Amended) A method for the treatment of an inflammatory disease or disorder in a subject in need of the treatment, comprising administering an inflammatory disease or disorder treatment effective amount of a composition to said subject, wherein the composition comprises boswellic acids, and wherein the boswellic acids consist essentially of acetyl-11-keto- β -boswellic acid, and wherein said subject is a human or animal.

Claim 177. (Previously Presented) The method of claim 148, wherein said subject is a human.

Claim 178. (Previously Presented) The method of claim 175, wherein said subject is a human.

Claim 179. (Currently Amended) A method for the treatment of an inflammatory disease or disorder in a subject in need of the treatment, comprising administering an inflammatory disease or disorder treatment effective amount of a composition to said subject, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14% to 65% by weight,
acetyl- β -boswellic acid of 5% to 65% by weight,
11-keto- β -boswellic acid of 5% to 60% by weight and
acetyl-11-keto- β -boswellic acid of 5% to 60% by weight,

wherein said subject is a human or animal, and wherein the % by weight is based on the total weight of the composition.

Claim 180. (Currently Amended) The method of claim 179, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14% to 55% by weight,
acetyl- β -boswellic acid of 10% to 55% by weight,
11-keto- β -boswellic acid of 5% to 50% by weight and
acetyl-11-keto- β -boswellic acid of 5% to 50% by weight.

Claim 181. (Currently Amended) The method of claim 180, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14% to 35% by weight,
acetyl- β -boswellic acid of 10% to 35% by weight,
11-keto- β -boswellic acid of 5% to 40% by weight and
acetyl-11-keto- β -boswellic acid of 5% to 40% by weight.

Claim 182. (Previously Presented) The method of claim 179, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14% by weight,
acetyl- β -boswellic acid of 5% by weight,
11-keto- β -boswellic acid of 5% by weight and
acetyl-11-keto- β -boswellic acid of 60% by weight.

Claim 183. (Previously Presented) The method of claim 180, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14% by weight,
acetyl- β -boswellic acid of 10% by weight,
11-keto- β -boswellic acid of 5% by weight and
acetyl-11-keto- β -boswellic acid of 50% by weight.

Claim 184. (Previously Presented) The method of claim 181, wherein the composition comprises three boswellic acids selected from the group consisting of

β -boswellic acid of 14% by weight,
acetyl- β -boswellic acid of 10% by weight,
11-keto- β -boswellic acid of 5% by weight and
acetyl-11-keto- β -boswellic acid of 40% by weight.

Claim 185. (Previously Presented) The method of claim 179, wherein the subject is a human.

Claim 186. (Previously Presented) The method of claim 180, wherein the subject is a human.

Claim 187. (Previously Presented) The method of claim 181, wherein the subject is a human.

Claim 188. (Previously Presented) The method of claim 182, wherein the subject is a human.

Claim 189. (Previously Presented) The method of claim 183, wherein the subject is a human.

Claim 190. (Previously Presented) The method of claim 184, wherein the subject is a human.

Claim 191. (Canceled)